Neuland Laboratories
Neuland Laboratories Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Neuland Laboratories
Start SIPNeuland Laboratories Investment Rating
-
Master Rating:
-
Neuland Laboratories has an operating revenue of Rs. 1,007.22 Cr. on a trailing 12-month basis. An annual revenue de-growth of 0% needs improvement, Pre-tax margin of 9% is okay, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 12%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 93 which is a GREAT score indicating consistency in earnings, a RS Rating of 64 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 107 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|
Oper Rev Qtr Cr | 294 | 221 | 256 |
Operating Expenses Qtr Cr | 225 | 193 | 217 |
Operating Profit Qtr Cr | 69 | 28 | 39 |
Depreciation Qtr Cr | 13 | 13 | 12 |
Interest Qtr Cr | 3 | 3 | 3 |
Tax Qtr Cr | 15 | 3 | 2 |
Net Profit Qtr Cr | 38 | 10 | 22 |
Neuland Laboratories Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 1
- Bearish Moving Average
- ___
- 15
- 20 Day
- 1539.75
- 50 Day
- 1593.09
- 100 Day
- 1550.2
- 200 Day
- 1481.17
- 20 Day
- 1575.13
- 50 Day
- 1646.33
- 100 Day
- 1574
- 200 Day
- 1373.88
Neuland Laboratories Resistance and Support
Resistance | |
---|---|
First Resistance | 1459.14 |
Second Resistance | 1519.52 |
Third Resistance | 1590.04 |
RSI | 33.64 |
MFI | 13.16 |
MACD Single Line | -52.47 |
MACD | -69.8 |
Support | |
---|---|
First Resistance | 1328.24 |
Second Resistance | 1257.72 |
Third Resistance | 1197.34 |
Neuland Laboratories Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 33,771 | 1,454,179 | 43.06 |
Week | 35,110 | 1,465,149 | 41.73 |
1 Month | 28,842 | 1,424,781 | 49.4 |
6 Month | 63,245 | 2,203,443 | 34.84 |
Neuland Laboratories Result Highlights
Neuland Laboratories Synopsis
NSE-Medical-Diversified
Neuland Laborat is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 951.08 Cr. and Equity Capital is Rs. 12.90 Cr. for the Year ended 31/03/2022. Neuland Laboratories Ltd. is a Public Limited Listed company incorporated on 07/01/1984 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L85195TG1984PLC004393 and registration number is 004393.Market Cap | 1,835 |
Sales | 1,007 |
Shares in Float | 0.82 |
No of funds | 56 |
Yield | 0.35 |
Book Value | 2.21 |
U/D Vol ratio | 0.9 |
LTDebt / Equity | 12 |
Alpha | 0.13 |
Beta | 0.74 |
Neuland Laboratories
Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
---|---|---|---|---|
Promoters | 36.14% | 36.22% | 36.22% | |
Mutual Funds | 0.79% | 0.79% | 0.79% | |
Foreign Portfolio Investors | 17.7% | 17.68% | 17.37% | |
Financial Institutions/ Banks | ||||
Individual Investors | 30.09% | 31.02% | 33.25% | |
Others | 15.28% | 14.29% | 12.37% |
Neuland Laboratories Management
Name | Designation |
---|---|
Dr. Davuluri Rama Mohan Rao | Executive Chairman |
Mr. Davuluri Sucheth Rao | Vice Chairman & CEO |
Mr. Davuluri Saharsh Rao | Vice Chairman & Mng.Director |
Dr. Christopher M Cimarusti | Non Executive Director |
Mr. Humayun Dhanrajgir | Ind. Non-Executive Director |
Mrs. Bharati Rao | Ind. Non-Executive Director |
Dr. Nirmala Murthy | Ind. Non-Executive Director |
Mr. Parampally Vasudeva Maiya | Ind. Non-Executive Director |
Mr. Homi Rustum Khusrokhan | Ind. Non-Executive Director |
Neuland Laboratories Forecast
Price Estimates
Neuland Laboratories Corporate Action
Neuland Laboratories FAQs
What is Share Price of Neuland Laboratories ?
Neuland Laboratories share price is ₹1420 As on 05 February, 2023 | 19:13
What is the Market Cap of Neuland Laboratories ?
The Market Cap of Neuland Laboratories is ₹1822 Cr As on 05 February, 2023 | 19:13
What is the P/E ratio of Neuland Laboratories ?
The P/E ratio of Neuland Laboratories is 22 As on 05 February, 2023 | 19:13
What is the PB ratio of Neuland Laboratories ?
The PB ratio of Neuland Laboratories is 2.2 As on 05 February, 2023 | 19:13